This announcement is a separate document:
华仁药业：关于全资子公司盐酸罂粟碱原料药获得上市申请批准通知书的公告
Huaren Pharmaceutical: Notice on the Wholly-owned Subsidiary Obtaining a Notice of Approval of the Marketing Application for Papaverine Hydrochloride API
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.